Modality
Bispecific Ab
MOA
KRASG12Ci
Target
JAK1
Pathway
Incretin
RSVPV
Development Pipeline
Preclinical
~Jun 2013
→ ~Sep 2014
Phase 1
~Dec 2014
→ ~Mar 2016
Phase 2
~Jun 2016
→ ~Sep 2017
Phase 3
~Dec 2017
→ ~Mar 2019
NDA/BLA
~Jun 2019
→ ~Sep 2020
Approved
Dec 2020
→ May 2030
ApprovedCurrent
NCT04395472
1,810 pts·PV
2022-05→2030-05·Not yet recruiting
NCT06383142
1,616 pts·PV
2020-12→2029-09·Terminated
NCT04835676
1,967 pts·RSV
2023-05→2026-01·Active
5,393 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2026-01-043mo agoPh3 Readout· RSV
2029-09-183.5y awayPh3 Readout· PV
2030-05-184.1y awayPh3 Readout· PV
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Approved
Termina…
Approved
Not yet…
Approved
Active
Catalysts
Ph3 Readout
2026-01-04 · 3mo ago
RSV
Ph3 Readout
2029-09-18 · 3.5y away
PV
Ph3 Readout
2030-05-18 · 4.1y away
PV
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04395472 | Approved | PV | Not yet recr... | 1810 | FEV1 |
| NCT06383142 | Approved | PV | Terminated | 1616 | Mayo |
| NCT04835676 | Approved | RSV | Active | 1967 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| ALN-6288 | Alnylam | Approved | LAG-3 |